Engineering molecular nanoprobes to target early atherosclerosis: Precise diagnostic tools and promising therapeutic carriers.

Q1 Pharmacology, Toxicology and Pharmaceutics Nanotheranostics Pub Date : 2023-01-01 DOI:10.7150/ntno.82654
Chunfang Zan, Jie An, Zhifang Wu, Sijin Li
{"title":"Engineering molecular nanoprobes to target early atherosclerosis: Precise diagnostic tools and promising therapeutic carriers.","authors":"Chunfang Zan,&nbsp;Jie An,&nbsp;Zhifang Wu,&nbsp;Sijin Li","doi":"10.7150/ntno.82654","DOIUrl":null,"url":null,"abstract":"<p><p>Atherosclerosis, an inflammation-driven chronic blood vessel disease, is a major contributor to devastating cardiovascular events, bringing serious social and economic burdens. Currently, non-invasive diagnostic and therapeutic techniques in combination with novel nanosized materials as well as established molecular targets are under active investigation to develop integrated molecular imaging approaches, precisely visualizing and/or even effectively reversing early-stage plaques. Besides, mechanistic investigation in the past decades provides many potent candidates extensively involved in the initiation and progression of atherosclerosis. Recent hotly-studied imaging nanoprobes for detecting early plaques mainly including optical nanoprobes, photoacoustic nanoprobes, magnetic resonance nanoprobes, positron emission tomography nanoprobes, and other dual- and multi-modality imaging nanoprobes, have been proven to be surface functionalized with important molecular targets, which occupy tailored physical and biological properties for atherogenesis. Of note, these engineering nanoprobes provide long blood-pool residence and specific molecular targeting, which allows efficient recognition of early-stage atherosclerotic plaques and thereby function as a novel type of precise diagnostic tools as well as potential therapeutic carriers of anti-atherosclerosis drugs. There have been no available nanoprobes applied in the clinics so far, although many newly emerged nanoprobes, as exemplified by aggregation-induced emission nanoprobes and TiO<sub>2</sub> nanoprobes, have been tested for cell lines <i>in vitro</i> and atherogenic animal models <i>in vivo</i>, achieving good experimental effects. Therefore, there is an urgent call to translate these preclinical results for nanoprobes into clinical trials. For this reason, this review aims to give an overview of currently investigated nanoprobes in the context of atherosclerosis, summarize relevant published studies showing applications of different kinds of formulated nanoprobes in early detection and reverse of plaques, discuss recent advances and some limitations thereof, and provide some insights into the development of the new generation of more precise and efficient molecular nanoprobes, with a critical property of specifically targeting early atherosclerosis.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 3","pages":"327-344"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093416/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanotheranostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7150/ntno.82654","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3

Abstract

Atherosclerosis, an inflammation-driven chronic blood vessel disease, is a major contributor to devastating cardiovascular events, bringing serious social and economic burdens. Currently, non-invasive diagnostic and therapeutic techniques in combination with novel nanosized materials as well as established molecular targets are under active investigation to develop integrated molecular imaging approaches, precisely visualizing and/or even effectively reversing early-stage plaques. Besides, mechanistic investigation in the past decades provides many potent candidates extensively involved in the initiation and progression of atherosclerosis. Recent hotly-studied imaging nanoprobes for detecting early plaques mainly including optical nanoprobes, photoacoustic nanoprobes, magnetic resonance nanoprobes, positron emission tomography nanoprobes, and other dual- and multi-modality imaging nanoprobes, have been proven to be surface functionalized with important molecular targets, which occupy tailored physical and biological properties for atherogenesis. Of note, these engineering nanoprobes provide long blood-pool residence and specific molecular targeting, which allows efficient recognition of early-stage atherosclerotic plaques and thereby function as a novel type of precise diagnostic tools as well as potential therapeutic carriers of anti-atherosclerosis drugs. There have been no available nanoprobes applied in the clinics so far, although many newly emerged nanoprobes, as exemplified by aggregation-induced emission nanoprobes and TiO2 nanoprobes, have been tested for cell lines in vitro and atherogenic animal models in vivo, achieving good experimental effects. Therefore, there is an urgent call to translate these preclinical results for nanoprobes into clinical trials. For this reason, this review aims to give an overview of currently investigated nanoprobes in the context of atherosclerosis, summarize relevant published studies showing applications of different kinds of formulated nanoprobes in early detection and reverse of plaques, discuss recent advances and some limitations thereof, and provide some insights into the development of the new generation of more precise and efficient molecular nanoprobes, with a critical property of specifically targeting early atherosclerosis.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
靶向早期动脉粥样硬化的工程分子纳米探针:精确的诊断工具和有前途的治疗载体。
动脉粥样硬化是一种炎症驱动的慢性血管疾病,是造成破坏性心血管事件的主要原因,带来严重的社会和经济负担。目前,非侵入性诊断和治疗技术结合新型纳米材料以及已建立的分子靶点正在积极研究中,以开发集成的分子成像方法,精确地可视化和/或甚至有效地逆转早期斑块。此外,过去几十年的机制研究提供了许多强有力的候选者,广泛参与动脉粥样硬化的发生和进展。近年来,用于早期斑块检测的成像纳米探针研究非常热门,主要包括光学纳米探针、光声纳米探针、磁共振纳米探针、正电子发射断层扫描纳米探针以及其他双模和多模成像纳米探针,这些纳米探针已被证明具有重要分子靶点的表面功能化,具有适合动脉粥样硬化的物理和生物特性。值得注意的是,这些工程纳米探针提供了长血池驻留和特异性分子靶向,可以有效识别早期动脉粥样硬化斑块,从而作为一种新型的精确诊断工具以及抗动脉粥样硬化药物的潜在治疗载体。虽然许多新出现的纳米探针,如聚集诱导发射纳米探针和TiO2纳米探针,已经在体外细胞系和体内致动脉粥样硬化动物模型中进行了测试,取得了良好的实验效果,但目前还没有应用于临床的纳米探针。因此,迫切需要将这些纳米探针的临床前结果转化为临床试验。因此,本综述旨在对目前研究的纳米探针在动脉粥样硬化中的应用进行概述,总结不同类型的纳米探针在斑块早期检测和逆转中的应用,讨论其最新进展及其局限性,并为开发新一代更精确、更高效的分子纳米探针提供一些见解。具有专门针对早期动脉粥样硬化的关键特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nanotheranostics
Nanotheranostics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
10.40
自引率
0.00%
发文量
37
审稿时长
12 weeks
期刊最新文献
Therapeutic Potential of Feline Adipose-Derived Stem Cell Exosomes in the Treatment of Feline Idiopathic Cystitis: A Characterization and Functional Analysis of miRNA Content. Development and assessment of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) for the rapid diagnosis of pleural tuberculosis. Development and optimization of dapagliflozin oral nano-bilosomes using response surface method: in vitro evaluation, in vivo evaluation. Preparation and Characterization of Carbon Nanodots from turmeric soot for anti-coliform and anti-oral bacterial applications and as anti-staphylococcal coatings. Erratum: Functionalized MoS2 Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy: Erratum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1